Table 2.
Differences in plasma p-tau181 and GFAP according to participants’ characteristics
| n | Plasma p-tau181 (pg/mL) | p-value | n | Plasma GFAP (pg/mL) | p-value | |
|---|---|---|---|---|---|---|
| mean (SD) | mean (SD) | |||||
| Sex | 0.023a | 0.005c | ||||
| Female | 163 | 13.0 (5.5) | 158 | 194.2 (85.5) | ||
| Male | 126 | 14.6 (6.1) | 125 | 168.3 (67.6) | ||
| Age | 0.002b | 0.001b | ||||
| 70 to 74 years | 70 | 11.8 (4.3) | 69 | 151.1 (50.1) | ||
| 75 to 79 years | 111 | 14.1 (5.4) | 109 | 187.3 (76.6) | ||
| 80 to 84 years | 82 | 13.9 (6.8) | 79 | 194.8 (97.4) | ||
| ≥85 years | 26 | 16.6 (5.6) | 26 | 210.9 (67.5) | ||
| Education (n=288) | 0.440b | 0.231b | ||||
| ≤7 years | 24 | 14.6 (5.3) | 23 | 190.7 (64.4) | ||
| 8 to 9 years | 45 | 14.4 (4.7) | 44 | 200.2 (62.9) | ||
| ≥10 years | 219 | 13.5 (6.0) | 215 | 178.7 (83.0) | ||
| Body mass index | 0.121b | <0.0001b | ||||
| <21 kg/m2 | 23 | 16.3 (6.3) | 22 | 238.2 (106.6) | ||
| 21 to 24.9 kg/m2 | 100 | 13.2 (5.7) | 96 | 194.5 (85.0) | ||
| ≤ 25 to 29.9 kg/m2 | 115 | 13.8 (5.9) | 115 | 174.6 (70.8) | ||
| ≥30 kg/m2 | 51 | 13.2 (5.2) | 50 | 154.4 (52.5) | ||
| APOE ε4 status (n=275) | 0.002a | 0.312a | ||||
| ε4 carrier | 68 | 15.4 (6.1) | 68 | 191.2 (75.2) | ||
| ε4 non-carrier | 207 | 13.0 (5.3) | 202 | 179.9 (80.6) | ||
| CDR score | 0.001a | 0.023c | ||||
| 0 | 122 | 12.4 (5.7) | 119 | 170.5 (70.0) | ||
| 0.5 | 167 | 14.7 (5.7) | 164 | 191.6 (84.1) | ||
| Amyloid status (PET) (n=46) | 0.046a | 0.238a | ||||
| Positive | 8 | 16.5 (4.9) | 8 | 201.0 (62.4) | ||
| Negative | 38 | 12.6 (5.0) | 38 | 171.7 (63.1) |
APOE, apolipoprotein E gene; CDR, Clinical Dementia Rating; GFAP, glial fibrillary acidic protein; PET, positron emission tomography; p-tau181, phosphorylated tau at threonine 181; SD, standard deviation; n=289, a Equal variance two sample t-test;.b ANOVA F-test; c Unequal variance two sample t-test.